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Abstract 
The steady aging of the population of developed countries increases the proportion of cardiovascular diseases in the overall 
structure of the incidence, which leads to an increase in the number of elderly patients in the practice of doctors of many 
specialties. Currently, there is an increase in the frequency of cardiovascular diseases, including acute coronary syndrome 
(ACS), while in the Russian Federation due to ACS there is a high mortality rate from sudden cardiac death (SCD). The aim of 
the work is a comparative analysis of the effect of mineralocorticoid receptor antagonists (MRA) of eplerenone on the predictors 
of SCD development in patients with ST elevation myocardial infarction (STEMI) with a moderately abnormal ejection 
fraction(EF) of the left ventricle (LV) in the early stages of the disease. Materials and methods. A total of 52 patients with 
STEMI who underwent myocardial reperfusion were examined. Patients are divided into 2 groups by age. 26 patients of middle 
age and 26 patients of elderly. The average age of the patients of the 1st group was 57.6 ± 10.5 years, 2 groups: 69.04 ± 2.02, 
the mean indicators of LVEF - 35.34 ± 4.7%. All patients were examined in the first and thirtieth days of rehabilitation treatment. 
The dynamics of indicators of BCC predictors (dispersion of the QT interval and its parts with correction using the Bazett 
formula) were assessed: QTd, QTcd, QTapd, JTd, JTapd, SubTd, SubTcd (ms). Results. In a comparative analysis of the effect 
of MRA on day 30, eplerenone in middle-aged patients had a significantly greater effect on the corrected QT interval: reducing 
the QTd interval by 16.7%; Δ18.06 ms (p = 0.38), QTcd by 23.7%; Δ27.94 ms (p = 0.024), QTapd by 20.1%; Δ3.1 ms (p = 
0.031), JTapd by 14.5%; Δ17.4 ms (p = 0.043), SubTcd by 12.8% Δ14.7 ms (p = 0.043) in relation to treatment in elderly 
patients. 
 
1. INTRODUCTION 
       
Currently, there is an increase in the frequency of 
cardiovascular diseases (CVD) [1], including acute 
coronary syndrome (ACS), while in the Russian 
Federation due to ACS, there is still a high mortality rate 
[2]. Since the number of elderly people is rapidly 
growing all over the world, and the clinical 
manifestations of CVDs increase dramatically with age, 
it is believed that prolongation of life expectancy of the 
population will have an increasingly significant burden 
on healthcare expenditures. It should be noted that 
today, aging is highlighted by the dominant factor of the 
risk of developing CVD. At the same time, in elderly 
people, an aging heart is characterized by both structural 
and functional changes. It should be noted that today in 
European countries in 51% of cases, ST elevation 
myocardial infarction (STEMI) (angioplasty or 
stenting), and in 41% - thrombolytic therapy [1]. 
However, a new approach in the treatment of patients 
with STEMI, Ming et al and Gonzalez et al detected that 
ASDs (DM) of the left ventricle (LV), opened in 2004, 
when the influence of the mineralocorticoid receptor 
antagonists (MRA) eplerenone was found on the 
prognosis in patients with STEMI [3,4,5]. Until 
recently, there was an opinion about the need for only 
symptomatic treatment of CVD in elderly and elderly 
patients and the non-significant effect of medical 
intervention on the prognosis of life at this age. 
However, recent large clinical studies convincingly 
indicate that the patient's age is not a contraindication to 
the active medical and surgical treatment of many 
CVDs - coronary heart disease (CHD), stenotic 
arteriosclerosis of the arteries, heart rhythm and 
conduction disturbances. 
Studying the effect of MRA on the incidence of 
sudden cardiac death of ARIA [6,7] established their 
positive effect on reducing overall mortality by 13%, 
and ARIA - by an absolute 3%. The main factor of the 
antifibrotic action of spironolactone is the inhibition of 
the formation of an extra-cellular matrix, which is 
confirmed by the highest survival of patients in the 
group with a reduced level of N-terminal particles of 
type III procollagen - plasma markers of collagen 
synthesis [8]. Thus, there is a slowdown in electrical 
remodeling of the myocardium and, accordingly, a 
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decrease in the probability of SCD [9]. In conditions of 
ischemia, where there is an elevation of the ST segment, 
measurement of the wave is difficult for determining the 
repolarization time only on the basis of the T wave. This 
is especially true of the central zone of ischemia, where 
the ST offset reaches its maximum in 20-30 minutes. In 
clinical terms, more significant changes in the 
dispersion are associated with the main 
pathophysiological states of the myocardium, such as 
acute myocardial ischemia, myocardial infarction 
[10,11]. 
At the same time, the effect of MRA on the blockade 
of aldosterone, the restoration of hibernated 
myocardium in patients with ACS after reperfusion has 
not been studied and is of particular significant interest. 
The question of the comparative effect of various MRA 
on electrical remodeling of myocardium remains 
unknown, especially in the early periods after STEMI in 
patients undergoing myocardial perfusion, depending 
on the structural, functional and hemodynamic features 
that formed the basis of this study. 
 
Objective  
 
To provide a comparative analysis of the effect of 
MRA eplerone and spironolactone on the dynamics of 
the dispersion of the QT interval and its parts in patients 
with STEMI with reduced EF in the early stages of the 
disease. 
 
Materials and Methods  
 
A comparative analysis of the effect of MRA - 
eplerenone on the predictors of sudden cardiac death 
was performed in patients with STEMI with a 
moderately abnormal ejection fraction(EF) of the left 
ventricle (LV) in the early stages of the disease. Patients 
were examined at admission to the Center for 
Cardiovascular Surgery of the Belgorod Regional 
Clinical Hospital of St. Joasaph, with a reduced LV EF 
<40% (average LV EF - 35.34 ± 4.7%). A total of 52 
patients with STEMI who underwent myocardial 
reperfusion were examined. Patients are divided into 2 
groups by age. 26 middle-aged patients and 26 elderly 
patients. The average age of patients in group 1 was 57.6 
± 10.5 years, 2 groups: 69.04 ± 2.02. All patients were 
examined in the first and thirtieth days of rehabilitation 
treatment. The dynamics of indicators of BCC 
predictors (dispersion of the QT interval and its parts 
with correction based on Bazett's formula) were 
evaluated: QTd, QTcd, QTapd, JTd, JTapd, SubTd, 
SubTcd (ms). The average age of patients was 57.6 ± 
10.5 years. The severity of heart failure during 
hospitalization before recovery of myocardial 
reperfusion was assessed according to the Killip 
classification: class I - 35%, II - 50%, III - 15%. The 
patients underwent myocardial reperfusion during the 
first 3 hours after the onset of the disease: thrombolytic 
therapy and percutaneous coronary intervention with 
stenting. Also, the criterion for inclusion in the study 
was the hemodynamically stable course of the disease 
after revascularization; in general, systolic arterial 
pressure (BP) in the group was 132.8 ± 25 mm Hg. Art., 
diastolic blood pressure - 82.9 ± 14 mm Hg. Art., 
functional class (FC) of chronic heart failure (CHF) at 
discharge was on average 1.7 ± 0.15. 
All patients underwent standard therapy for 
STEMI: double anti-thiagregant therapy, direct 
anticoagulants (unfractionated heparin and low-
molecular heparins, statins, β-adrenergic blockers, ACE 
inhibitors, diuretics, MRA - eplerenone (Espiro, 
Akrichin), diuretics, diuretics; at two stages: before the 
reperfusion treatment on the 1st day of the STEMI upon 
admission to the Department of anaesthesiology and 
pain therapy and on the 30th day after 
revascularization.The control group consisted of 30 
people comparable in age and sex with patients who 
underwent STEMI, after the survey, physical th 
examination, research laboratory data registration 
electrocardiography (ECG) and echocardiography 
(echocardiographic) no evidence of clinically 
significant cardiovascular disease. 
The study of the clinical condition of the patients 
was performed using standard techniques. A standard 
ECG with registration was performed using a 
SCHILLER AT-1 (2004) 12-channel 
electrocardiograph at a speed of 50 mm / s. The study 
determined the following intervals: QT, QTd, QTcd, 
JTd, JTacd, SubTd, SubTcd. Correction of the duration 
of the interval and its parts was carried out according to 
the formula of Bazett (ms). EchoCG was performed on 
an Philips En Visor C echocardiograph (USA, 2005) 
with a 3.5 MHz multi-frequency electronic sensor 
Vivid-7 (USA, 2004) according to the standard 
technique. The following indicators were evaluated: 
end-systolic volume (KSO, cm2), final-diastolic volume 
(KDO, cm2); ejection fraction (PV,%), systolic pressure 
in the pulmonary artery (SDLA, mm Hg). 
Statistical processing of the data was carried out on 
a personal computer using the variation statistics 
method using the Microsoft Excel and Statictica 10.0 
software [12]. The comparison of groups was performed 
using non-parametric criteria: two independent 
selections - Mann-Whitney and Wald-Wolfowitz, for 
linked samples - the sign criterion and the Wilcoxon 
criterion in the form of mean and standard deviation (M 
± SD). For a comparative analysis of the effect of the 
two drugs on the indices of the dispersion of the QT 
interval plots, and identifying the prevailing therapy for 
30 days, we used the non-parametric Friedmann test 
(Friedman’s ANOVA Kendall method). The 
significance of differences was determined at a given 
level of significance, p <0.05 [13]. 
 
Results  
 
A comparative analysis of the indicators of the QT 
interval and its parts in patients with AIMSPST on the 
first day before the reperfusion with similar indicators 
of the control group demonstrated a statistically 
significant increase in the group of patients examined. 
Thus, the average value of the QTd interval before 
myocardial revascularization was higher than the 
control group by 2.73 times (p = 0.000000), and the 
QTcd indicators were 3.1 times (p = 0.000000). At the 
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same time, there is a significant change in the indicator 
in the DIMSPST group with a low LV ejection fraction 
of JTd which was increased 6 times (p = 0.000000), and 
JTcd - 6.9 times (p = 0.000000), SubTd - 5 times (p = 
0.000000), and SubTcd - 5.8 times (p = 0.000000) (table 
1). 
 
Table 1. Analysis of the cardiac cycle intervals in patients with STEMI in the first day before reperfusion (М±SD) 
Indicators, ms Control group 
n=30 
Main group  
n=52 
p 
 
1 2 1-2 
QRS  113.70±19.90 110.66±19.24 0.000000 
QTd 34.70±2.74 95.00±20.68 0.000000 
QTcd 36.04±3.19 113.45±28.93 0.000000 
QT apd 24.90±2.42 102.31±17.01 0.000000 
QT apcd 25.87±2.79 103.28±20.78 0.000000 
JTd  15.76±2.31 95.00±20.68 0.000000 
JTcd  16.37±2.45 113.45±28.69 0.000000 
JTapd  15.10±2.70 111.18±18.21 0.000000 
JTapcd  15.71±3.08 112.36±22.21 0.000000 
Sub Td 14.86±2.83 75.70±16.84 0.000000 
Sub Tcd 15.46±3.12 90.19±22.59 0.000000 
 
From the data obtained it is clear that the dispersion of 
the QT interval changes to a greater extent due to its final 
segment, which, apparently, primarily responds to 
myocardial ischemia and speaks in favor of the occurrence 
of fatal ventricular tachyarrhythmias in patients with 
STEMI without restoring myocardial reperfusion. 
Analysis of the structural and geometric indices of the 
heart in patients with STEMI during hospitalization on the 
first day before reperfusion revealed a significant decrease 
in EF by more than 43.7% (p = 0.000000) compared to the 
control group, and an increase in the volume of the LV 
cavity was established both due to BWW by 35.5% (p = 
0.000007), and to a greater extent - CSR, which, due to 
myocardial infarction, was increased 2.3 times (p = 
0.000000). Before the reperfusion of myocardium in the 
main group, a significantly high change in the indices of 
SDLA was determined compared to the control group, 
which was increased by 1.7 times (p = 0.000000) (Table 
2). 
 
Table 2. Analysis of structural and geometric parameters of the heart in patients with OIMspST on the first day before 
myocardial reperfusion (M±SD) 
Indicators Control group 
n=30 
Main group 
n=52 
P 
1 2 1-2 
EF LV, % 61.44±5.16 35.18±5.46 0.000000 
EDV LV, ml 107.83±8.26 150.43±40.25 0.000007 
EDV 53.99±6.10 73.59±24.55 0.000125 
ESV LV, ml 41.33±4.48 98.50±31.56 0.000000 
TIS, sm 0.91±0.08 1.26±0.16 0.000000 
TPWLV, sm 0.89±0.08 1.18±0.15 0.000000 
SPPA, mm hg 25.47±1.87 43.24±14.88 0.000000 
MMLV, g/m2 177.21±18.63 284.75±17.32 0.021644 
iMMLV 88.77±12.41 135.69±0.52 0.021644 
 
The effect on LV remodeling processes in patients 
after ACS by administering MRA is quite an important 
phenomenon, since remodeling is associated with 
activation of neurohormones, as well as various cytokines 
and growth factors, synthesis of free radicals by oxygen, 
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apoptosis and collagen formation, and all these factors 
increase the risk of SCD [14,15].  
MRA improves heart rate variability and baroreceptor 
function, reducing the activation of the sympathetic 
nervous system. All these effects, each of which can 
contribute to a reduction in mortality, are realized in the 
early period after ACS. Therefore, it is likely that it is the 
cumulative effect of the blockade of aldosterone, and not 
any one individual mechanism, that is responsible for the 
positive effect of eplerenone on total mortality within 30 
days after randomization in the EPHESUS study [4]. 
However, the study of the differentiated effect of MRA in 
patients with STEMI undergoing myocardial reperfusion 
was not carried out, which is of particular interest. In our 
study, subsequently, patients of the general group were 
divided into 2 subgroups depending on the received MRA. 
Blocking the coronary blood flow entails a sequence 
of pathophysiological changes, in particular, areas of 
necrosis, apaptosis, hibernation of cardiomyocytes, 
ultimately leading to remodeling of the 
electrophysiological properties of the myocardium as a 
whole. Nevertheless, in spite of the complete recovery of 
myocardial reperfusion, in our patients in our work there 
was a reliably significant trend towards an increase in the 
indicators of electrical instability of the myocardium, 
without positive dynamics. 
A comparative analysis of the effect of MRA 
eplerenone in different age groups on the indicators of 
electrical instability of the myocardium in patients with 
STEMI with reduced LV EF for 30 days determined that 
the reception in elderly patients eplerenone did not have a 
significant positive effect, but it had a positive trend to 
decrease indicators of corrected parts of the QT interval. 
At the same time, a significant improvement in the 
contractile function of the LV by 10.14% (p <0.05) was 
found. In the group of patients with STEMI with LV EF 
<40% on the 30th day of eplerenone intake in middle age, 
a significant positive decrease in the corrected indices was 
found. So QTd decreased by 16.7%, which amounted to 
Δ18.06 ms (p = 0.038), QTсd - by 23.7%; Δ27.94 ms (p = 
0.024), QTapd - by 20.1%; Δ3.1 ms (p = 0.031), JTapd - 
by 14.54%; Δ17.4 ms (p = 0.041), SubTcd - by 12.8%; 
Δ14.7 ms (p <0.05), which significantly exceeds the 
figures for treatment in the group of elderly patients (p 
<0.05) (table 3), to a greater extent in corrected indicators. 
 
Table 3. Comparative analysis of the effect of EPLERENON on the electrical instability of the myocardium in patients 
with STEMI with an LV ejection fraction of <40% elderly and middle age on day 30 after reperfusion therapy (M±SD) 
Indicato
rs 
Group 1 
 n=26 
Group 2 
n=26 
Р 
1 point  
 
2 point 
 
1 point  
 
2 point  
 
1
-2 
3
-4 
5-6 
1 2 3 4 5 6 7# 
QRS, 
ms 
115.78±2
1.61 
112.36±2
0.54 
100.0±10.
27 
98.6±12
.94 
1
.000 
1
.000 
0.1 
QTd, ms 107.81±2
6.83 
100.30±1
0.44 
108.32±2
7.49 
90.24±0
.03 
0
.088 
0
.038 
0.0
10 
QTсd, 
ms 
117.14±1
4.82 
110.20±4.
26 
118.11±1
0.43 
90.16±0
.04 
0
.087 
0
.024 
0.0
10 
QT apd, 
ms 
107.12±1
9.66 
107.04±1
5.43 
105.42±1
1.14 
79.31±9
.42 
0
.179 
0
.031 
0.0
07 
QT 
apcd, ms 
110.22±1
6.42 
108.34±1
4.72 
107.84±2
1.24 
80.04±1
0.18 
0
.134 
0
.01 
0.0
00 
JTd, ms 99.83±11.
94 
91.23±7.3
7 
94.71±18.
57 
90.42±1
0.42 
0
.059 
0
.173 
0.0
98 
JTcd, 
ms 
116.84±4.
83 
110.37±5.
64 
98.78±11.
32 
81.22±6
.07 
0
.067 
0
.01 
0.0
00 
JTapd, 
ms 
118.73±2
1.41 
111.82±1
1.21 
119.62±1
6.45 
102.2±7
.86 
0
.066 
0
.041 
0.0
38 
JTapcd, 
ms 
120.52±1
1.32 
106.65±1
0.24 
121.33±1
1.06 
100.03±
6.87 
0
.119 
0
.011 
0.0
00 
SubTd, 
ms 
105.91±1
7.29 
100.24±9.
59 
104.63±2
0.43 
98.83±1
4.43 
0
.075 
0
.089 
0.0
67 
SubTcd, 
ms 
112.73±1
6.92 
109.33±8.
87 
115.21±1
0.28 
100.52±
9.61 
0
.088 
0
.039 
0.0
43 
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In our study, a comparative analysis was 
conducted of the effect of the dynamics of MRA drug 
correction of eplerenone in patients of different age 
groups (elderly and middle age) on the structural and 
geometric parameters of the heart in patients with 
STEMI 30 days after myocardial reperfusion (Table 
4).  
 
Table 4. Analysis of the effect of the dynamics of drug correction of eplerenone in elderly and middle-aged patients 
with STEMI on the structural and geometric parameters of the heart on day 30 after myocardial reperfusion (M±SD) 
Indicators 
Group 1 
 n=26 
Group 2 
n=26 
Р 
1 point  
 
2 point 
 
1 point  
 
2 point  
 
1
-2 
3
-4 
5
-6 
1 2 3 4 5 6 
7
# 
LVEF, % 35.09±5.8
0 
38.65±6.1
7 
35.37±4.9
9 
43.04±5.5
0 
0
.003 
0.
006 
0
.076 
EDV LV, 
ml 
146.26±39
.77 
152.39±3
6.24 
159.22±4
2.19 
150.00±3
3.74 
0
.142 
0.
044 
0
.027 
EDV 75.27±25.
04 
78.91±21.
03 
76.98±22.
93 
64.88±18.
62 
0
.49 
0.
037 
0
.044 
ESV LV, 
ml 
96.74±30.
36 
94.24±29.
67 
104.33±3
5.07 
89.66±26.
16 
0
.960 
0.
015 
0
.004 
TWLV, 
sm 
1.28±0.17 1.26±0.16 1.22±0.15 1.20±0.61 0
.960 
1.
000 
1
.000 
TPWLV, 
sm 
1.20±0.16 1.19±0.16 1.12±0.14 1.10±0.13 0
.971 
0.
971 
1
.000 
SPPA, 
mm hg 
42.09±11.
40 
35.85±8.1
2 
45.67±21.
10 
32.71±5.1
9 
0
.070 
0.
023 
0
.006 
MMLV, 
g/m2 
287.03±0.
16 
280.04±1.
21 
284.75±1
7.32 
272.58±1
1.15 
0
.971 
0.
044 
0
.027 
iMMLV 139.21±0.
33 
137.19±0.
51 
135.69±0.
52 
119.96±2.
09 
0
.971 
0.
037 
0
.027 
It was found that additional eplerenone therapy in 
middle-aged patients also had an additional positive 
effect on LV structural and functional parameters. 
Thus, LV EF increased by 21.68%; Δ7.67% (p = 
0.006), LV CLV decreased by 5.8%; Δ9,22 ml (p = 
0.044), the indexed index of the differential 
differential effect of LV decreased by 15.7%; Δ-12,1 
ml (p = 0.037). At the same time, the effect on the 
decrease in LV CSR by 14.06% was proved; Δ-14,67 
ml (p = 0,015), which was reflected in the decrease in 
SLEA by 28.4%; Δ-12.96 mm Hg (p = 0.023). 
Significant decrease in both MM by 4.27%; Δ-12,17, 
(p = 0.044) and IMM by 11.6%; Δ-15.73 (p = 0.037). 
 
Conclusion 
 
The prognostic role of corrected QT interval in 
ST-elevation myocardial infarction is still unknown. 
This study aims to identify the prognostic value of 
corrected QT interval prolongation in acute coronary 
syndrome. A comparative analysis of the degree of 
influence of eplerenone therapy in patients of different 
age groups (middle-aged and elderly) for 30 days 
showed in our study that the effect of eplerenone on 
30 days in middle-aged patients was significantly 
superior to the effect of eplerenone in patients with 
corrected QT interval indicators: dQTd, dQTcd, 
dQTapd, dQTapcd, JTcd, dJTapd, dJTapcd, dSubTcd. 
It is noteworthy that when assessing the effect on 
markers of electrical myocardial instability in the 
elderly, they did not significantly reduce them, having 
only a tendency to decrease. It was established that 
eplerenone in the middle-age group had a significant 
significant impact on all indicators of the QT interval: 
dQTd, dQTapd, dJTapd, dSubTd. There is also a 
significant improvement on the 30th day of the effect 
of eplerenone in the middle age group and on the 
structural and functional indicators of the left ventricle 
such as: dFV LV, dKDO LV, dKSO LV, dSDLA. 
Increased dispersion of the QT interval (QTd) was 
found in patients with acute myocardial infarction, it 
was subsequently shown that this index decreases with 
thrombolytic therapy. So, Lörincz et al. Evaluated the 
effect of intravenous streptokinase on QT and JT 
dispersions and found that QTd increased in the first 
hours after a heart attack and thrombolytic therapy, but 
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decreased 8 ± 2 hours after it was performed [16,17]. 
Subsequently, QT and JT intervals were determined 
by predictors of the effect on all-cause mortality, 
regardless of the duration of the QRS interval, with 
some advantage of using JT. Our study aimed at 
identifying risk factors associated with the lack of 
dispersion dynamics of the QT interval after coronary 
artery reperfusion in patients with ACS, STEMI 
revealed that dilatation of the left ventricle is an 
independent factor that does not reduce the variance of 
the corrected QTcd index. The scientific work on the 
study and evaluation of individual intervals that make 
up the QT interval as separate indicators of 
repolarization is very important. 
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